Bullbearadvisor 
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical company headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK. Founded in 2003, Summit focuses on the discovery, development, and commercialization of therapies aimed at addressing serious unmet medical needs, particularly in oncology. Their lead investigational therapy, ivonescimab (also known as SMT112), is a novel bispecific antibody targeting both PD-1 and VEGF, designed to enhance anti-tumor activity. Ivonescimab is currently undergoing multiple Phase III clinical trials, including the HARMONi series, for the treatment of non-small cell lung cancer and other solid tumors. In January 2023, Summit entered into a collaboration and license agreement with Akeso Inc. for the development and commercialization of ivonescimab in various territories, including the United States, Canada, Europe, and others. Summit Therapeutics -+1GlobalData+1Reuters+1Summit Therapeutics -+1Summit Therapeutics -+2Summit Therapeutics -+2Reuters+2
Over the past 52 weeks, Summit Therapeutics' stock has experienced a low of $2.10 and a high of $36.91. Barchart.com+7WallStreetZen+7Robinhood+7
Analyst recommendations for Summit Therapeutics are as follows:
- Buy: 10 analysts
- Hold: 0 analysts
- Sell: 0 analystsPitchBook+16Bloomberg+16Robinhood+16
This results in a consensus rating of "Buy" based on evaluations from 10 analysts.
Subscribe to our API. See Strong Buy and Sell Signals the Day after They Occur!
